Expert Interview
A Third View: Investigating the Phase 2 COMP004 clinical trial data on COMP360 psilocybin in patients with treatment resistant depression.
Ticker(s): CMPSInstitution: Southcentral Foundation
- Psychiatry & Addiction Medicine specialist at SouthCentral Foundation in Alaska.
- Currently manages 40 patients a week and referred many patients for ketamine but has not prescribed it directly herself yet.
- comfortable discussing the results from the EBS-B Study (Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers) which were recently presented at the CNS Summit 2023 in Boston.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
